SCHEMBL16268355

SCHEMBL16268355

COc1nc(Cl)nc(Br)c1N

nearest known ligand 0.40

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6639436 0.84 CYP1A2 (0.47) CYP1A2
SCHEMBL23657132 0.77 CYP1A2 (0.41) CYP1A2
SCHEMBL30696307 0.77 CYP1A2 (0.41) CYP1A2
SCHEMBL16268194 0.75 CYP1A2 (0.44) CYP1A2
SCHEMBL22161839 0.71 CYP1A2 (0.37) CYP1A2
SCHEMBL22161930 0.69 CYP1A2 (0.36) CYP1A2
SCHEMBL9432184 0.69 CYP1A2 (0.61) CYP1A2
SCHEMBL22162234 0.68 CYP1A2 (0.35) CYP1A2
SCHEMBL22161922 0.68 CYP1A2 (0.35) CYP1A2
SCHEMBL22119900 0.68 ALDH1A1 (0.47) CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3004118-B1 USE OF CONDENSED BENZO[B]THIAZINE DERIVATIVES AS CYTOPROTECTANTS ARANDA PHARMA LTD (FI) 2018-12-19 EP disclosed
US-9827249-B2 Use of condensed benzo[B]thiazine derivatives as cytoprotectants ARANDA PHARMA LTD (FI) 2017-11-28 US disclosed
US-9827249-B2 Use of condensed benzo[B]thiazine derivatives as cytoprotectants ARANDA PHARMA LTD (FI) 2017-11-28 US disclosed
US-9827249-B2 Use of condensed benzo[B]thiazine derivatives as cytoprotectants ARANDA PHARMA LTD (FI) 2017-11-28 US disclosed
US-20160106754-A1 USE OF CONDENSED BENZO[B]THIAZINE DERIVATIVES AS CYTOPROTECTANTS ARANDA PHARMA LTD (FI) 2016-04-21 US disclosed
US-20160106754-A1 USE OF CONDENSED BENZO[B]THIAZINE DERIVATIVES AS CYTOPROTECTANTS ARANDA PHARMA LTD (FI) 2016-04-21 US disclosed
US-20160106754-A1 USE OF CONDENSED BENZO[B]THIAZINE DERIVATIVES AS CYTOPROTECTANTS ARANDA PHARMA LTD (FI) 2016-04-21 US disclosed
EP-3004118-A1 USE OF CONDENSED BENZO[B]THIAZINE DERIVATIVES AS CYTOPROTECTANTS Aranda Pharma Ltd (FI) 2016-04-13 EP disclosed
WO-2014191632-A1 USE OF CONDENSED BENZO[B]THIAZINE DERIVATIVES AS CYTOPROTECTANTS MEDEIA THERAPEUTICS LTD (FI) 2014-12-04 WO disclosed
WO-2014191632-A1 USE OF CONDENSED BENZO[B]THIAZINE DERIVATIVES AS CYTOPROTECTANTS MEDEIA THERAPEUTICS LTD (FI) 2014-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160106754-A1 USE OF CONDENSED BENZO[B]THIAZINE DERIVATIVES AS CYTOPROTECTANTS TXN2, GPX4, NQO1 CYP1A2 580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.